Prognostic impact of apoptosis marker Fas (CD95) and its ligand (FasL) on bladder cancer in Egypt: Study of the effect of schistosomiasis

ecancermedicalscience

Volumn 6, Issue 1, 2012, Pages

  Elmansy, Hazem M ^a   Kotb, A F ^b   Hammam, O ^c   AbdelRaouf, H ^d   Salem, H K ^d   Onsi, M ^d   ElLeithy, T ^e  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b ALEXANDRIA UNIVERSITY   (Egypt)

^c Theodor Bilharz Research Institute   (Egypt)

^d Cairo University   (Egypt)

^e Egypt   (Egypt)

Author keywords

Apoptosis; Bladder carcinoma; Fas; Fas ligand; Schistosomiasis

Indexed keywords

FAS ANTIGEN; FAS LIGAND; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER STAGING; CHRONIC BILHARZIAL CYSTITIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTITIS; EGYPT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; SCHISTOSOMIASIS;

EID: 84869389256     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2012.278     Document Type: Article

References (18)

1. Wyllie AH (1992) Apoptosis and the regulation of cell numbers in normal and neoplastic tissues: An overview Cancer Metastasis Rev 11 95-103 DOI: 10.1007/BF00048057 PMID: 1394797
2. Tineke T, Elisabeth GE and Steven J (2002) Fas receptor mediated apoptosis: a clinical application J Phathol 196 125-34 DOI: 10.1002/path.1028
3. Nagata S (1997) Apoptosis by death factor Cell 88 355-65 DOI: 10.1016/S0092-8674(00)81874-7 PMID: 9039262
4. Yamana K, Bilim V, Hara N, Kasahara T, Itai T, Marujama R, Nishiyama T, Takahashi K and Tomita Y (2005) Prognostic impact of Fas/CD95/Apo-1 in urothelial cancers: decreased expression of Fas is associated with disease progression Br J Cancer 93 544-51 DOI: 10.1038/sj.bjc.6602732 PMID: 16091761 (Pubitemid 43079997)
5. Suda T, Takahashi T, Goldstein R and Nagata S (1993) Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family Cell 75 1169-78 DOI: 10.1016/0092-8674(93)90326-L PMID: 7505205 (Pubitemid 24006113)
6. Bellgrau D, Gold D, Selawry H et al (1995) A role for CD95 ligand in preventing graft rejection Nature 337 630-2 DOI: 10.1038/377630a0
7. Lee SH, Lee JY, Park WS, Kim SY, Jang JJ and Yoo NJ (1999) Transitional cell carcinoma expresses high levels of Fas ligand in vivo BJU Int 85 698-702 (Pubitemid 29164312)
8. Muscheck M, Abol-Enein H, Chew K, Moore D, Bhargava V, Ghoneim MA, Carroll PR and Waldman FM (2000) Comparison of genetic changes in schistosome-related transitional and squamous bladder cancers using comparative genomic hybridization Carcinogenesis 21(9) 1721-6 DOI: 10.1093/carcin/21.9.1721 PMID: 10964104
9. Haitel A, Posch B, El-Baz M, Mokhtar AA, Susani M, Ghoneim MA and Marberger M (2001) Bilharzial related, organ confined, muscle invasive bladder cancer: Prognostic value of apoptosis markers, Proliferation markers, p53, E- Cadherin, epidermal growth factor receptor and C-erb-2 J Urol 165(5) 1481-7 DOI: 10.1016/S0022-5347(05)66332-X PMID: 11342901 (Pubitemid 32410219)
10. Arase H, Arase N and Saito T (1995) Fas-mediated cytotoxicity by freshly isolated natural killer cells J Exp Med 181 1235-8 DOI: 10.1084/jem.181.3.1235 PMID: 7532682
11. Thompson C (1995): Apoptosis in the Pathogenesis and Treatment of Disease. Science, 267: 1456-62. DOI: 10.1126/science.7878464 PMID: 7878464
12. Chopin D, Barei-Monini, Maille P, Le Frere-Belda MA, Muscatelli-Groux B, Merendino N, Lecerf L, Sloppacciaro A, Velotti F (2003) Human urinary bladder transitional cell carcinoma acquire the functional Fas ligand during tumor progression Am J Pathol 162(4) 1139-49 DOI: 10.1016/S0002-9440(10)63910-7 PMID: 12651606
13. Eble JN, Sauter G, Epstein JI and Sesterhenn I (2004) World Health Organization Classification of tumors. Pathology and genetics of tumors of the urinary system and male genital organs (Lyon: IARC Press)
14. Hsu SM, Raine L and Fauger H (1981) Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase technique: a comparison between ABC and unlabelled antibody (PAP) procedure J Histochem 29 577-80
15. Itoi T, Yamana K, Bilim VN, Takahashi K and Tomita Y (2004) Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients Br J Cancer 90 200-5 DOI: 10.1038/sj.bjc.6601454 PMID: 14710230 (Pubitemid 38174962)
16. El-Baz HG, El-Demerdash Z, Hammam O, El-Baz AG and Hanallah S (2004) Circulating soluble Fas and Fas antigen tissue expression in human bladder cancer Med J Cairo Univ 209-19
17. Mass S, Warskulat U, Steinhoff C, Muller W, Grimm MO, Schulz WA and Seifert HH (2004) Decreased Fas expression in advanced stage bladder cancer is not related to P 53 status Urology 63 392-7 DOI: 10.1016/j.urology.2003.08.023 (Pubitemid 38234453)
18. Mehmut M, Takeda K, Abe M, Ogata H, Hirose S, Okumura K and Fujime M (2005) Fas ligand and TNF- related apoptosis inducing ligand induction on infiltration lymphocytes in bladder carcinoma by bacillus Camlett-Guerin treatment Urol Int 75(1): 80-7 DOI: 10.1159/000085934 PMID: 16037714 (Pubitemid 41022600)